RecruitingNCT05917106
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
Sponsor
Jinling Hospital, China
Enrollment
450 participants
Start Date
Dec 26, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.
Eligibility
Inclusion Criteria6
- Newly diagnosed renal cell carcinoma
- Without any treatment
- Agree and accept radical surgical treatment
- Signed written informed consent
- ECOG(Eastern Cooperative Oncology Group) performance is 0 or 1
- Follow up protocol and related procedures
Exclusion Criteria6
- Had other cancers
- Had received any antitumor therapy before
- Known or suspected active autoimmune disease
- Informed consent is not possible due to medical or psychiatric problems
- Have clinical symptoms or diseases of the heart that are not well controlled
- Patients judged by the investigators to be unsuitable for inclusion in this study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05917106
Related Trials
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
NCT0498150913 locations
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
NCT000268841 location
Anatomical-Clinical Base of Adenocarcinoma Pancreatic
NCT061283438 locations
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT0711504311 locations
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
NCT057386948 locations